Form 4: MapLight CSO Sells 51,707 Shares via 10b5-1 Plan

Chief Scientific Officer James Woodruff sold 51,707 shares of MapLight Therapeutics common stock between May 4 and May 6, 2026, under a pre-arranged trading plan.

Summary

• James Woodruff, Chief Scientific Officer of MapLight Therapeutics, executed a series of stock sales totaling 51,707 shares.
• The transactions occurred over three days, from May 4, 2026, to May 6, 2026.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.
• Following these transactions, the reporting person retains 243,450 shares of voting common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and do not indicate a change in the company's fundamental outlook.

Positives

• The sales were executed under a pre-established Rule 10b5-1 plan, which is designed to avoid concerns regarding insider trading by scheduling sales in advance.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's future valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to diversify their personal portfolios and should not be interpreted as a lack of confidence in the company's long-term strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.
• The volume of shares sold is consistent with typical executive liquidity events in the biotechnology sector.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns regarding potential non-public information usage.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Selling, Form 4, Chief Scientific Officer, Rule 10b5-1